pp-018 Injection, pre-filled pen 300 IU/0.72 mg/3 ml
Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
Long-acting insulin analogue and GLP-1 combination injection in Phase 3 for type 2 diabetes mellitus. Monotherapy using dual hormone action to improve glycemic control. Same class as insulin degludec/liraglutide and insulin glargine/lixisenatide.
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days